» Articles » PMID: 33227047

CPEB1 Orchestrates a Fine-tuning of MiR-145-5p Tumor-suppressive Activity on TWIST1 Translation in Prostate Cancer Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2020 Nov 23
PMID 33227047
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

TWIST1 is a basic helix-loop-helix transcription factor, and one of the master Epithelial-to-Mesenchymal Transition (EMT) regulators. We show that tumor suppressor miR-145-5p controls TWIST1 expression in an immortalized prostate epithelial cell line and in a tumorigenic prostate cancer-derived cell line. Indeed, shRNA-mediated miR-145-5p silencing enhanced TWIST1 expression and induced EMT-associated malignant properties in these cells. However, we discovered that the translational inhibitory effect of miR-145-5p on TWIST1 is lost in 22Rv1, another prostate cancer cell line that intrinsically expresses high levels of the CPEB1 cytoplasmic polyadenylation element binding protein. This translational regulator typically reduces TWIST1 translation efficiency by shortening the TWIST1 mRNA polyA tail. However, our results indicate that the presence of CPEB1 also interferes with the binding of miR-145-5p to the TWIST1 mRNA 3'UTR. Mechanistically, CPEB1 binding to its first cognate site either directly hampers the access to the miR-145-5p response element or redirects the cleavage/polyadenylation machinery to an intermediate polyadenylation site, resulting in the elimination of the miR-145-5p binding site. Taken together, our data support the notion that the tumor suppressive activity of miR-145-5p on TWIST1 translation, consequently on EMT, self-renewal, and migration, depends on the CPEB1 expression status of the cancer cell. A preliminary prospective study using clinical samples suggests that reconsidering the relative status of miR-145-5p/TWIST1 and CPEB1 in the tumors of prostate cancer patients may bear prognostic value.

Citing Articles

The Roles of Cytoplasmic Polyadenylation Element Binding Protein 1 in Tumorigenesis.

Li J, Wu Y, Zhang D, Zhang Z, Li S, Cheng X Mini Rev Med Chem. 2024; 24(22):2008-2018.

PMID: 38879767 DOI: 10.2174/0113895575293544240605112838.


Pro-tumorigenic role of lnc-ZNF30-3 as a sponge counteracting miR-145-5p in prostate cancer.

Le Hars M, Castro-Vega L, Rajabi F, Tabatadze D, Romero M, Pinskaya M Biol Direct. 2023; 18(1):38.

PMID: 37434219 PMC: 10334624. DOI: 10.1186/s13062-023-00393-7.


miR-145-5p Inhibits Neuroendocrine Differentiation and Tumor Growth by Regulating the SOX11/MYCN Axis in Prostate cancer.

Ji S, Shi Y, Yang L, Zhang F, Li Y, Xu F Front Genet. 2022; 13:790621.

PMID: 35368699 PMC: 8965462. DOI: 10.3389/fgene.2022.790621.

References
1.
Sramkoski R, Pretlow 2nd T, Giaconia J, Pretlow T, Schwartz S, Sy M . A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 1999; 35(7):403-9. DOI: 10.1007/s11626-999-0115-4. View

2.
Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T . MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer. 2011; 130(3):611-21. DOI: 10.1002/ijc.26064. View

3.
Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A . Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat. 2008; 11(4-5):123-51. DOI: 10.1016/j.drup.2008.07.001. View

4.
Degeorges A, Hoffschir F, Cussenot O, Gauville C, Le Duc A, Dutrillaux B . Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line. Int J Cancer. 1995; 62(6):724-31. DOI: 10.1002/ijc.2910620613. View

5.
Hornik C, Brand-Saberi B, Rudloff S, Christ B, Fuchtbauer E . Twist is an integrator of SHH, FGF, and BMP signaling. Anat Embryol (Berl). 2005; 209(1):31-9. DOI: 10.1007/s00429-004-0412-3. View